Ras signaling pathways are well-recognized for their involvement in cancer cell proliferation; however, considerably less is known regarding their contribution to invasion and metastasis. Here, we demonstrate that a novel BLT2, a low-affinity leukotriene B 4 receptor-linked signaling cascade involving the generation of reactive oxygen species (ROS) via Nox1, NF-jB stimulation and subsequent upregulation of matrix metalloproteinase-9 (MMP-9) is a potential mechanism by which Ras promotes invasion and metastasis. We found that inhibition of BLT2 signaling markedly suppressed Ras-evoked metastasis and reduced the associated mortality in mice. Consistent with the proposed role of BLT2 as a key downstream mediator of Ras signaling to metastasis, BLT2 expression alone resulted in the formation of numerous metastatic lung nodules and the nodules formation was significantly attenuated by the inhibition of MMP-9, a downstream component of BLT2. Together, our results reveal the previously unsuspected function of BLT2-linked cascade in driving oncogenic Ras-induced metastasis and would provide a valuable insight into invasion and metastasis.
Introduction
The Ras gene is the most frequently mutated oncogene detected in human cancers, and aberrant activation of Ras has been implicated in facilitating virtually all aspects of a malignant phenotype, including proliferation, invasion and metastasis (Bos, 1989; Campbell and Der, 2004) . Ras-induced invasion and metastasis are accompanied by a number of biochemical changes, including activation of Raf-mitogen-activated protein kinase, phosphatidylinositol 3-kinase, and Rho family GTPases (Downward, 2003; Campbell and Der, 2004; Giehl, 2005) . In addition, overexpression of the protooncogene Met and its ligand hepatocyte growth factor/ scatter factor or extracellular matrix-degrading protease activity by stimulation of the transcription factor NFkB may be possible routes by which oncogenic Ras triggers invasion and metastasis (Yang et al., 2001) . Over the past several years, arachidonic acid metabolites, collectively known as eicosanoids, have been shown to have roles in cancer-related inflammation and metastasis (Nie et al., 2001; Ding et al., 2003) . Eicosanoids are usually derived from cytosolic phospholipase A2-released arachidonic acid (Brock and Peters-Golden, 2007) . The released arachidonic acid is further metabolized by three enzymatic pathways: the cyclooxygenase (COX), lipoxygenase (LO) and cytochrome P450-dependent pathways. COX2-induced production of prostaglandins is implicated in the regulation of tumor-associated angiogenesis and metastasis (Harris, 2007; Wang et al., 2007) . It was previously reported that oncogenic Ras regulates COX-2 expression for cellular transformation (Van Putten et al., 2001) and enhances matrix metalloprotease (MMP)-9 activity through the activation of ERK1/2 and NF-kB to expand invasive potential .
Another arachidonate metabolic enzyme, 5-lipoxygenase (5-LO) and its bio-products, including the leukotrienes, have also been implicated in cancer cell proliferation and progression (Nie et al., 2001; Romano and Claria, 2003; Ding et al., 2005; Hennig et al., 2005) . Unlike COX, however, role of the 5-LO and LT products in the tumor-associated invasion and metastasis are not yet shown. Leukotriene B 4 (LTB 4 ), the first isolated LT, elicits a variety of inflammatory responses, including leukocyte activation, chemotaxis and degranulation (Woo et al., 2002; Iizuka et al., 2005) . LTB 4 exerts its biological effects by binding to its cognate receptors, BLT1 and BLT2 (Choi et al., 2008) . Most studies of LTB 4 receptors have focused on the high-affinity receptor, BLT1, which is expressed exclusively in inflammatory cells, such as leukocytes, and has a role in inflammatory processes (Yokomizo et al., 1995) . In contrast, BLT2, a low-affinity LTB 4 receptor is expressed in a wide variety of tissues (Yokomizo et al., 2000) . Although no clear physiological function has yet been identified for BLT2, its expression was shown to be markedly upregulated by oncogenic Ras and to mediate the generation of reactive oxygen species (ROS) (Choi et al., 2008) .
In this study, we analysed the potential roles of leukotrienes in Ras-induced invasion and metastasis. Surprisingly, we found that the BLT2 cascade has a potential role in mediating the invasion of Rastransformed cells via elevation of MMP-9 activity. Furthermore, when cells were tail-vein injected into athymic nude mice (to test experimental metastasis), the metastatic potential of Ras-transformed cells was dramatically suppressed by BLT2-specific inhibition, as measured by counting the number and size of metastatic nodules formed in the lungs, as well as by histological analysis. In addition, tail-vein injection of cells overexpressing BLT2, but not control cells, into mice produced numerous metastatic lung nodules in an MMP-9-dependent manner, suggesting that BLT2 induction is sufficient to drive metastasis. Together, our results suggest that a BLT2-linked cascade may contribute to Ras-induced tumor progression by enhancing metastatic potential.
Results
The BLT2-NOX1-ROS-linked signaling cascade mediates Ras-induced invasiveness In agreement with a previous report (Choi et al., 2008) , the expression of BLT2, but not BLT1, is elevated by Ras, as detected by immunocytochemical staining of Rat2-HO6 cells (Yoo et al., 2004) , which are transformed Rat-2 cells that stably express H-Ras V12 Figure 1 Ras-induced invasiveness is dependent on BLT2 signaling. (a) Rat-2, Rat2-HO6 and Rat2-BLT2 cells were fixed, permeabilized and stained with anti-BLT1 and anti-BLT2 antibodies. Representative images of three independent experiments. Bar, 100 mm. (b) Rat2-HO6 and Rat2-BLT2 cells show enhanced invasiveness. Rat-2 (l), Rat2-HO6 (ll) and Rat2-BLT2 cells (lll) (5 Â 10 4 cells) were loaded into the upper wells of Matrigel-invasion chambers, and 300 nM LTB 4 was added to the lower well. After 24 h, cells that had invaded the lower well were stained and quantified. Bar, 100 mm. Data are from the analysis of 10 microscopic fields from five independent experiments and are expressed as the mean relative to control Rat-2 cells invaded (25 ± 13 cells) ± s.d. Statistical significance was assessed using an unpaired t-tests. The invasion (c) or migration assay (d) was performed, as described in the Supplementary information. For inhibition experiments, cells were pre-treated with 10 mM of LY255283 or 1 mM of U75302 for 30 min or were transfected with control siRNA (scrambled) or 50 nM of siBLT2. After 24 h, the number of cells that had migrated through the Matrigel matrix was quantified. Data are from the analysis of 10 microscopic fields from five independent experiments and are expressed as the mean relative to control Rat-2 cells invaded or migrated (c; 24 ± 8 cells, d; 38 ± 12 cells) ± s.d. Statistical significance was assessed using unpaired t-tests.
( Figure 1a ). The level is comparable with or higher than the levels observed in Rat2-BLT2 cells stably expressing BLT2 (Yoo et al., 2004) . Similarly, by FACS or semiquantitative RT-PCR analysis, expression of BLT2, but not BLT1 (data not shown), was shown to be increased in Rat-2 or NIH3T3 cells transiently or stably expressing H-Ras V12 (Supplementary Figure 1) . Next, we examined whether BLT2 expression contributes to Ras-driven invasiveness. The invasion assays were performed using an invasion chamber coated with Matrigel, as described under Supplementary information. As shown in Figure 1b , oncogenic Ras strongly enhanced the invasiveness of cells, and BLT2 expression also significantly enhanced invasiveness, albeit to a lesser extent than Ras (Figure 1b) . The enhanced invasiveness driven by oncogenic Ras was significantly attenuated by the selective BLT2 antagonist LY255283 (Yokomizo et al., 2001; Shin et al., 2006) or by siBLT2 RNA interference, but not by the BLT1 antagonist U75302, in both Rat2-HO6 cells and NIH3T3-HRas V12 cells (Figure 1c) . Similarly, oncogenic Ras expression in Rat-2 or NIH3T3 cells resulted in significantly enhanced migration toward chemotactic factors, such as LTB 4 , using transwell migration assays and these activities were also blocked by LY255283 or by siBLT2, but to a much lesser extent by U75302 (Figure 1d ). Taken together, these results suggest that BLT2 upregulation is necessary for Ras-induced invasiveness.
Recently, we reported that ROS generation by Nox1, a protein related to gp91 phox /Nox2 of phagocytes, is a key downstream signaling mechanism by which BLT2 mediates the transformation in Ras signaling (Choi et al., 2008) . To determine whether ROS production by BLT2-Nox1 activation is involved in Ras-induced invasiveness, we analysed the invasive activities of Rat2-HO6 and Rat2-BLT2 cells in the presence of ROS scavenging agents or by RNA interference using siNox1. Clearly, the enhanced invasiveness evoked by H-Ras V12 or BLT2 was significantly attenuated by pretreatment of the cells with N-acetylcysteine, a ROS scavenger, or diphenyleneiodonium, an inhibitor of flavoenzymes, such as NADPH oxidase (Figure 2a) . Similarly, the enhanced invasiveness was greatly reduced in siNOX1-transfected Rat2-HO6 cells (Figure 2b ). Taken together, these results show that ROS generated by the BLT2-Nox1 cascade are necessary for Rasinduced invasiveness. Consistent with this idea, we observed that the level of ROS was elevated in Rat2-HO6 or Rat2-BLT2 cells and that treatment with BLT2 antagonist or siNOX1 suppressed ROS generation in these cells (Supplementary Figure 2) . NF-kB lies downstream of the BLT2-ROS cascade in Ras-induced invasiveness ROS have previously been reported to affect redoxsensitive transcription factors, such as NF-kB or AP-1 (Hsu et al., 2000; Behrend et al., 2003) . Thus, we next examined whether activation of NF-kB or AP-1 is involved in oncogenic Ras-evoked invasiveness. As shown in Figure 3a , NF-kB promoter-dependent luciferase activity was highly enhanced in Rat-2 cells stably or transiently expressing H-Ras V12 or BLT2, but Figure 2 The BLT2-NOX1-ROS-linked cascade mediates Ras-induced invasiveness. (a) ROS generation by NADPH oxidase was required for the enhanced invasiveness evoked by H-Ras V12 or BLT2 overexpression. The cells were pre-treated with buffer, 2 mM of N-acetylcysteine (NAC), or 2 mM of diphenylene iodonium (DPI) for 30 min before the invasion assays. (b) Nox1 knockdown by siNox1 suppresses the enhanced invasiveness of Rat2-HO6 cells. At 36 h after transfection, the cells were assayed for invasiveness (lower panel), and Nox1 transcripts were assessed by semiquantitative RT-PCR using NOX1-specific primers (upper panel), as described previously (Choi et al., 2008) . All data are quantified from the analysis of 10 microscopic fields from five independent experiments and are expressed as the mean relative to control cells invaded (24 ± 4 cells) ± s.d. Statistical significance was assessed using unpaired t-tests. Role of BLT2 in Ras-driven invasion and metastasis E-Y Kim et al this effect was significantly reduced by pretreatment with LY255283 or the specific NF-kB inhibitor, pyrrolidine dithiocarbamate (PDTC), but not by pretreatment with U75302 or NS398, a COX inhibitor ( Figure 3b , left panel). In contrast, Ras-induced AP1 promoter activity was not affected by LY255283, although Ras was capable of stimulating AP-1 activity (Supplementary Figure 3a) . In addition, no stimulation of AP-1 promoter activity was observed in response to BLT2 expression (Supplementary Figure 3b) . These results indicate that AP-1 does not have a role in Ras-BLT2-signaling. To further elucidate the participation of NF-kB in 'Ras-BLT2-ROS' signaling, we performed an EMSA using nuclear extracts from Rat2-HO6 cells. The DNA-binding activity of NF-kB observed in Rat2-HO6 cells was markedly suppressed by pretreatment with PDTC or LY255283, but to a much lesser extent by U75302 ( Figure 3b , right panel). The NF-kB band disappeared when an unlabeled oligonucleotide was added to the reaction mixture ( Figure 3b , right panel; 
(a) NF-kB activation is induced by H-Ras
V12 or BLT2 overexpression. Rat-2 cells were transiently co-transfected with pcDNA3, pcDNA3-H-Ras V12 , pcDNA3-BLT1 or pcDNA3-BLT2 and the reporter plasmid pNF-kB-Luc containing the NF-kB promoter fused to a luciferasecoding sequence (left panel). Rat-2, Rat2-HO6 or Rat2-BLT2 cells were transiently transfected with the pNF-kB-Luc reporter plasmid, cultured for 24 h and then serum-starved for 12 h (right panel). The cells were then harvested and the relative luciferase activities were measured as described in Supplementary information. Data are expressed as fold increases relative to the control. Statistical significance was assessed using unpaired t-tests. *Po0.01. (b) The BLT2 antagonist LY255283 inhibits Ras-induced NF-kB activation. Rat-2 cells were transiently co-transfected with pcDNA3 or pcDNA3-H-Ras V12 and the pNF-kB-Luc reporter plasmid, cultured for 24 h and then serum-starved for 12 h before cell harvest. For the inhibition tests, cells were treated with 10 mM LY255283, 1 mM U75302, 100 mM PDTC or 20 mM NS398 for 6 h before cell harvest and then the relative luciferase activities were measured (left panel). Data are expressed as fold increases relative to the control. Statistical significance was assessed using unpaired t-tests. *Po0.01 and **Po0.001. In addition, EMSA was performed to detect enhanced NF-kB activation in Rat2-HO6 cells (right panel) as described in Supplementary information. Cells were treated with 100 mM PDTC, 10 mM LY255283, or 1 mM U75302 for 24 h before the EMSA assays and, as a negative control, a sample without nuclear extract (probe only, P) was subjected to EMSA. The addition of 100-fold molar excess of a competitor unlabeled oligonucleotide was used to verify the DNA-binding specificity of NF-kB. The NF-kB-DNA complex is indicated by the arrowhead. The results shown are representative of three independent experiments with similar results. (c) NF-kB activation is involved in the enhanced invasiveness evoked by H-Ras V12 or BLT2 overexpression. The cells were incubated in 100 mM of PDTC, 100 mM of NF-kB control peptide (SN-50M), 100 mM of NF-kB inhibitor peptide (SN-50), or control buffer and subjected to invasion assays. The invaded cells were fixed, stained and quantified as described in Supplementary information. Data are expressed as the mean relative to control Rat-2 cells invaded (24 ± 5 cells) ± s.d. n ¼ 5. Statistical significance was assessed using unpaired t-tests **Po0.001 and ***Po0.0001. (d) ROS generation via DPI-sensitive NOX1 is involved in H-Ras V12 -dependent NF-kB activation. Rat-2 cells were transiently co-transfected with pcDNA3 or pcDNA3-H-Ras V12 and a pNF-kB-Luc reporter plasmid and then incubated in the presence or absence of 2 mM N-acetylcysteine (NAC) or 2 mM DPI for 6 h before cell harvest (left panel), or Rat-2 cells were transiently co-transfected with pcDNA3-DN-NOX1 or pSIREN-siRNA-NOX1 and pcDNA3 or pcDNA3-H-Ras V12 and a pNF-kB-Luc reporter plasmid (right panel). Relative luciferase activity was determined and statistical significance was assessed using unpaired t-tests. *Po0.01 and **Po0.001. competitor), showing the specificity of DNA binding by NF-kB. Consistent with the potential role of NF-kB as a downstream component of a 'Ras-BLT2-ROS' cascade in invasiveness signaling, invasiveness was dramatically suppressed when Rat2-HO6 or Rat2-BLT2 cells were pre-treated with PDTC ( Figure 3c, left panel) . A similar suppressive effect was observed in response to treatment with a non-antioxidant NF-kB inhibitor, SN-50, but not SN-50M, a negative control peptide (Figure 3c , right panel). In addition, pretreatment with diphenylene iodonium or N-acetylcysteine, as well as Nox1 knockdown by DN-NOX1 (dominant negative NOX1) or siNOX1, significantly attenuated NF-kB activation (Figure 3d ), consistent with NF-kB functioning in a downstream position in the BLT2-Nox1-ROS cascade during Ras-induced invasiveness.
The 'BLT2-ROS-NF-kB' cascade stimulates MMP-9 to mediate Ras-induced invasiveness We were next interested in characterizing components further downstream in the 'BLT2-ROS-NF-kB' cascade and, thus, examined whether NF-kB activation is involved in the upregulation of MMP-9, which has been suggested to have a critical role in invasiveness and metastasis (Deryugina and Quigley, 2006) . MMP-9 is upregulated in a dose-dependent manner by transient expression of Ras or BLT2 in Rat-2 or NIH-3T3 cells (Figure 4a In contrast, pretreatment with the BLT1 antagonist U75032 or the cysteinyl leukotriene receptor-specific inhibitor LY171883 failed to attenuate Ras-induced MMP-9 upregulation (Figure 4c left panel) . The level of MMP-2 in Ras-transformed cells was not affected by either LY255283 or U75302 (data not shown), thus excluding the involvement of MMP-2 in Ras-BLT2-signaling. The addition of the BLT2 ligand LTB 4 further elevated MMP-9 activity in Rat-2 cells transiently transfected with pcDNA3-H-Ras V12 or pcDNA3-BLT2 (Figure 4c , left panel). In addition, both siNox1 and dnNox1 (dominant negative mutant of Nox1) blocked the increase in MMP-9 promoter activity induced by transient Ras transfection (Figure 4c , right panel). Taken together, our results suggest that MMP-9 is a downstream component of the Ras-BLT2-Nox1-NF-kB cascade. Next, we investigated the role of MMP-9 in Ras-or BLT2-induced invasiveness using siMMP-9 RNA interference. Using two different siRNAs specific for MMP-9, the MMP-9 level was clearly diminished (Figure 4d, left panel) , and the invasiveness of Rat2-HO6 or Rat2-BLT2 cells was almost completely suppressed ( Figure 4d , middle and right panels), further showing a role for MMP-9 in BLT2-mediated invasiveness.
The BLT2 axis is required for Ras-induced metastatic colonization in an animal model Next, to determine whether the BLT2-signaling cascade is also required for Ras-induced metastasis in vivo, we examined the in vivo metastatic potential of H-Ras V12 -expressing cells using an experimental metastasis assay in which the number and size of metastatic nodules formed in the lung were measured. Doses of 0.25 mg/kg of U75302 or 2.5 mg/kg of LY255283, similar to those used previously (Yoo et al., 2004) , were administered intraperitoneally 3 and 5 days after tail-vein injection of Rat2-HO6 cells. Mice were euthanized 21 days after cell inoculation, and pulmonary metastases were examined. Mortality was also monitored over 48 days. Figure 5a shows that Rat2-HO6 cells, but not parent Rat-2 cells (Supplementary Figure 5a) , were highly metastatic and formed a significant number of lung metastases, consistent with previous reports (Bondy et al., 1985; Su et al., 1993; Oft et al., 2002) . However, the size of metastatic lung nodules in mice injected with Rat2-HO6 cells was dramatically reduced by the administration of LY255283, but not by U75302 (Supplementary Figure  5b, upper panel) . Moreover, although mice injected with cells expressing H-Ras V12 formed a large number of perivascular metastatic deposits (dotted lines) based on histological analysis of the lungs, mice administrated LY255283 showed surprisingly fewer deposits (Figure 5a , upper panel). Both the number of metastatic nodules and the metastatic tumor burden were also markedly reduced by LY255283 administration (Figure 5a, lower panel) . Similar results were observed in mice injected with NIH3T3-HRas V12 cells (Supplementary Figure 5c) . Furthermore, all mice injected with Rat2-HO6 cells or Rat2-HO6 cells treated with control buffer or U75302 died or became moribund within the 3 weeks observation period. However, mice administered LY255283 suffered much lower mortality rates over the 48 days observation period (Figure 5b ). Consistent with BLT2 as a mediator of metastasis, overexpression of BLT2 also induced pulmonary metastases in nude mice, although the size and number of nodules was smaller than that observed in mice injected with cells expressing H-Ras V12 (Figure 5c , upper panel and Supplementary Figure 5b, lower panel) . Similarly, the increased number of lung nodules and metastatic tumor burden in mice injected with Rat2-BLT2 cells was also dramatically reduced by LY255283 (Figure 5c , lower panel), reverting back to levels observed in control mice. Furthermore, knockdown of BLT2 with siBLT2 in Rat2-HO6 or Rat2-BLT2 cells revealed a similar dramatic reduction in the number of lung nodules and metastatic tumor burden in mice injected with these cells (Figure 5d ). Together, these results clearly show that BLT2 signaling is potentially involved in Ras-evoked metastasis in vivo.
Inhibition of 'BLT2-MMP-9' signaling attenuates Ras-induced pulmonary metastasis To further ascertain the role of BLT2 signaling in metastasis in vivo, we examined the effect of SB-3CT, an inhibitor of MMP gelatinase activity (Gu et -or BLT2-induced metastasis and mortality. The same dose of SB-3CT (12.5 mg/kg) used in a previous report (Kruger et al., 2005) was injected intraperitoneally 3 and 5 days after tail-vein injection of Rat2-HO6 cells. Most mice in the control group died within 3 weeks after cell inoculation, whereas half of the SB-3CT-treated . Culture supernatants were analysed by western blot analysis to assess MMP-9 levels (b). For inhibitor tests, cells were treated with 10 mM of LY255283, 1 mM of U75302 or 0.1 mM of LY171883 for 6 h. To analyse the effect of LTB 4 , transfected cells were treated with 300 nM of LTB 4 for 6 h before cell harvest (left panel) or also transiently co-transfected with pcDNA3, pcDNA3-H-Ras V12 , pMMP-9-Luc and pcDNA3-DN-NOX1 or pSIREN-siRNA-NOX1 (right panel). Cells were harvested and relative luciferase activity was measured (c). Statistical significance was assessed using unpaired t-tests. *Po0.01 and **Po0.001. (d) Cells were transfected with a control siRNA (scrambled) or 50 nM of rat siRNA MMP-9 (oligos no. 1 or oligos no. 2) as described in Materials and methods. Culture supernatants were analysed by western blot analysis to assess MMP-9 levels (left panel). The levels of tubulin are shown as a loading control for the cell lysates. Also, siMMP-9 transfected Rat2-HO6 or Rat2-BLT2 cells were also subjected to Matrigel-invasion assays (right panel). Data are quantified from the analysis of 10 microscopic fields from five independent experiments and are expressed as the mean relative to control Rat-2 cells invaded (23 ± 7 cells) ± s.d. n ¼ 5. Statistical significance was assessed using unpaired t-tests. **Po0.001 and ***Po0.0001. mice survived for 48 days under these conditions (P ¼ 0.001; log-rank test) (Figure 6a ). Upon morphological analysis, the lungs of animals injected with Rat2-HO6 or Rat2-BLT2 and administered SB-3CT showed a reduction in the number of nodules, as well as metastatic tumor burden, compared with animals that Figure 5 In vivo metastatic potential evoked by H-Ras V12 is suppressed by BLT2 inhibition. (a) Mice were injected with Rat2-HO6 cells, and then administered DMSO (control), 2.5 mg/kg of LY255283, or 0.25 mg/kg of U75302 as described in Supplementary information. Mice were killed 21 days after cell injections, and the lungs sections (4 mm) were stained with H&E and photographed (upper panel) and the number of surface metastatic lung nodules and metastatic tumor burden were determined (lower panels). 
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did not receive SB-3CT treatment (Figure 6b ). Consistent with the suggested role of MMP-9 as a potential downstream component of the 'Ras-BLT2-ROS-NFkB' cascade in metastasis, immunohistochemical staining of metastatic lung lesions obtained from mice injected with Rat2-HO6 or Rat2-BLT2 displayed elevated levels of MMP-9 (Figure 6c, left panel) . In addition, knockdown of MMP-9 with siMMP-9 in Rat2-HO6 or Rat2-BLT2 cells revealed a similar dramatic reduction in the number of lung nodules and metastatic tumor burden in mice injected with these cells compared with control mice (Figure 6c, right panel) .
Together, these data strongly suggest that MMP-9 acts as a downstream component of Ras-BLT2 signaling in metastasis.
Discussion
In this study, we showed that the BLT2-linked pathway has a crucial role in invasion and metastatic activities associated with oncogenic Ras. In support of BLT2 as a mediator of invasion and metastasis, overexpression of Role of BLT2 in Ras-driven invasion and metastasis E-Y Kim et al BLT2 alone induced enhanced invasiveness in Matrigelinvasion assays and enhanced pulmonary metastasis in mice. Together, our results reveal a previously unsuspected function of the BLT2-linked pathway in driving oncogenic Ras-induced invasion and metastasis. In addition, we analysed the key components mediating the invasion and metastasis of Ras-transformed cells downstream of the BLT2 pathway and found that the 'NOX1-ROS-NF-kB-MMP-9' cascade is potentially downstream of BLT2.
Our results are consistent with previous reports suggesting that ROS are involved in the epithelialmesenchymal transition, migration and invasion of tumor cells by regulating cytoskeletal remodeling, extravasation, angiogenesis and genes associated with tumor metastasis (Wu, 2006) . Consistent with our results suggesting that MMP-9 is a downstream effector of the BLT2-Nox1-ROS cascade, MMPs have been shown to be critical in tumor cell invasion and metastasis (Yang et al., 2001; Deryugina and Quigley, 2006) . In many cancers, elevated plasma levels of soluble gelatinases positively correlate with a higher incidence of metastases and are considered valuable prognostic factors (Bjorklund and Koivunen, 2005; Nikkola et al., 2005) . In contrast to our results, however, previous studies reported that oncogenic Ras regulates COX-2 expression (Van Putten et al., 2001) and enhances MMP-9 activity through the activation of ERK1/2 and NF-kB, enhancing invasive potential . In addition, COX-2-derived prostaglandin E 2 induces the migration and adhesion of hepatocellular carcinoma cells through an integrin-dependent pathway (Mayoral et al., 2005) . Therefore, COX-2 may be a potential target for anti-metastatic agents (Chun and Surh, 2004; Cha and DuBois, 2007) . However, in contrast to these reports, we previously observed that COX is not involved in Ras signaling during transformation (Yoo et al., 2001) , and that the levels of COX-2 are unchanged in Rat2-HO6 cells compared with parental control cells (data not shown). Furthermore, these data clearly show that COX-2 inhibition by NS-398 did not affect NF-kB or AP-1 activation during Ras signaling (Figure 3b and Supplementary Figure 3a) , thus excluding a role for COX-2 in Ras signaling to invasiveness and metastasis, at least under our experimental conditions. The mechanisms associated with BLT2 or COX involvement in Ras signaling may vary depending on the cell type assessed (Subbaramaiah et al., 2002; Lee et al., 2006) .
In accordance with our findings regarding the role of the BLT2-linked cascade in Ras-induced invasiveness and metastasis, mounting evidence has implicated LTB 4 and its receptor BLTs in cancer progression (Hennig et al., 2005; Heukamp et al., 2006) . LTB 4 , a ligand for BLTs, has been suggested to stimulate cell proliferation in various cancer cell types, including colon and pancreatic cancer cell lines, and LTB 4 receptors are overexpressed in these cancer cells (Bortuzzo et al., 1996; Tong et al., 2002; Woo et al., 2002) . Blocking of BLTs, preferentially BLT1, by LY293111, inhibits proliferation and induces apoptosis in pancreatic cancer and lymphoma cells (Tong et al., 2002) . In addition, Hennig et al. (2005) reported that treatment with LY293111 reduces tumor growth and the incidence of metastasis in athymic mice, suggesting a potential role for BLTs in tumor progression in vivo. More recently, Rocconi et al. (2008) suggested that expression of BLT2, but not BLT1, in ovarian cancer tissues correlates with advanced stage III/IV disease and is associated with poor clinical outcomes. We observed that expression of BLT2, but not BLT1, was markedly increased in invasive or metastatic aggressive human cancer tissues compared with control non-neoplastic tissues (Supplementary Figure 6 ). The exact pathophysiological function of the high levels of BLT2 detected in human cancer tissues, however, requires further characterization. Interestingly, our recent preliminary results indicate that the level of BLT2 expression is elevated in proportion to advancing stages of bladder cancer specimens and that BLT2 inhibition by LY255283 or siBLT2 suppresses invasion and metastasis in human bladder cancer cells (Kim EY et al., unpublished observation) , suggesting that the BLT2-linked cascade may be a general signaling cascade responsible for metastasis of human cancers in vivo.
Consistent with BLT2 as a mediator of metastasis, overexpression of BLT2-induced pulmonary metastasis in mice (Figure 5c and Supplementary Figure 5b) , suggesting that BLT2 somehow possesses intrinsic metastatic capacity. We suspect that the enhanced invasiveness mediated by BLT2 (as shown in Figure 1 ) contributes considerably to the induced metastatic nodule formation in vivo (as shown in Figure 5 ), but, we cannot exclude the possibilities that other capacities of BLT2 might have roles in the Ras-evoked metastasis. In fact, we recently found that BLT2 is involved in vascular endothelial growth factor-induced angiogenesis in the vascular endothelium . In that study, we showed that while BLT2 stimulation does not induce any noticeable angiogenesis by itself, BLT2 can enhance or promote the angiogenesis caused by vascular endothelial growth factor, thus acting in a potentiating, but not triggering, role in angiogenesis. In addition, BLT2 was previously shown to be involved in Rasmediated transformation (Yoo et al., 2004; Choi et al., 2008) . Furthermore, we recently observed that the BLT2 cascade has a role in the pro-survival signal in estrogen receptor-negative breast cancer cells (Choi et al., 2009) , thus pointing to survival as another capacity of BLT2. Therefore, considering these results together with the present finding, BLT2 appears to be involved in multiple pleiotropic capacities (for example, cell proliferation, survival, invasiveness, metastasis and angiogenesis) during cancer progression, and we suspect that all these BLT2 activities may have roles, to a certain extent, in Ras-evoked metastasis in tumor microenvironments. Consistent with this speculation, when we searched for the optimum conditions to show the maximum contribution of BLT2 to Ras-evoked metastasis in vivo, we observed that 3 and 5 days after injection of BLT2 inhibitor worked best (as shown in Figure 5 ). We also tested BLT2 inhibitors at earlier times (1 and 3 days), but the suppressive effect was not as great as that from days 3 and 5 (data not shown). We suspect that the reason for this reduced efficacy may be associated with other potential capacities possessed by BLT2 in addition to invasiveness since the invasion step is suggested to occur quite rapidly during metastasis. Future studies will be necessary to understand the detailed underlying molecular mechanisms by which BLT2 contributes to Ras-evoked metastasis in the host microenvironment and/or to what extent the intrinsic BLT2 invasiveness capacity contributes to in vivo metastasis.
In any event, based on our observation, we propose a model that links the Ras-and BLT2-signaling pathways and leads to invasion and metastasis. As summarized in Figure 7 , our data reveal that upregulation of BLT2 by oncogenic Ras results in the generation of ROS via Nox1 and also that NF-kB and MMP-9 are potential downstream components of the BLT2-Nox1-ROS cascade, having potential roles in the invasive and metastatic activity associated with oncogenic Ras. This novel mechanism should contribute to a better understanding of the mechanisms of tumor invasion and metastasis.
Materials and methods
Chemicals and cell culture LTB4, LY171883 and a BLT2 antagonist LY255283 (Yokomizo et al., 2001; Qiu et al., 2006; Shin et al., 2006) were purchased from the Cayman Chemical Company (Ann Arbor, MI, USA). NS398, SN-50M, SN-50 (Zampetaki et al., 2005) and a BLT1 antagonist U75302 (Yokomizo et al., 2001; Qiu et al., 2006) were obtained from Biomol (Plymouth Meeting, PA, USA). Bovine serum albumin, phorbol-12-myristate-13-acetate, diphenylene iodonium and N-acetylcysteine were obtained from Sigma-Aldrich (St Louis, MO, USA). Pyrrolidine dithiocarbamate (PDTC) (Zampetaki et al., 2005) were obtained from Calbiochem (La Jolla, CA, USA) and SB-3CT was purchased from Chemicon (Temecula, CA, USA). Fetal bovine serum, Dulbecco's Modified Eagle's Medium (DMEM) and non-essential amino acids were obtained from Life Technologies Inc. (Gaithersburg, MD, USA). All other chemicals were from standard sources and were of molecular biology grade or higher. NIH3T3 (murine fibroblast cell line) and Rat-2 (rat fibroblast cell line) were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA). Rat-2 and Rat2-HO6 cells (Kumar et al., 1992) , pcDNA3-BLT1 encoding Flag-tagged human BLT1 and pcDNA3-BLT2 encoding HA-tagged human BLT2 (Yokomizo et al., 2000) , respectively, followed by selection with 0.4 mg/ml G418 (Invitrogen, Carlsbad, CA, USA), as described previously (Choi et al., 2008) .
RNA interference for BLT2, Nox1 and MMP-9 Scramble control and human BLT2-specific siRNA (for Rat2-BLT2 cells) were purchased from Ambion (Austin, TX, USA) using the following BLT2-target sequences as described previously (Hennig et al., 2008) . Rat BLT2-specific siRNA (for Rat-2 and Rat2-HO6 cells) was purchased from Bioneer (Daejeon, Korea) and RNA interference for rat BLT2 and Nox1 was performed as described previously (Choi et al., 2008) . Mouse BLT2-specific siRNA (for NIH-3T3, NIH3T3-HRas V12 cells) was purchased from Bioneer: siBLT2 (5 0 -CUCGGUUCCUUACUCGACUtt-3 0 ). Rat MMP-9-specific siRNA was purchased from Ambion. Based on the rat MMP-9 cDNA sequences, two different MMP-9 siRNAs were designed as follows: siMMP-9#1 (5 0 -CACUUACUUUGGAA ACGCAtt-3 0 ), siMMP-9#2 (5 0 -GAAGUUCUCGAAUCACG GAtt-3 0 ). For the RNA interference experiments, cells were plated at 4 Â 10 5 cells per 60-mm dish. After 24 h, the cells were transfected with 50 nM siRNA using Oligofectamine reagent (Invitrogen), according to the manufacturer's instructions. After 36 h, the mRNA levels of each gene were analysed by RT-PCR or real-time PCR to evaluate interference.
Immunohistochemical staining for BLT1, BLT2 and MMP-9 To localize BLT expression in cultured cells, Rat-2, Rat2-BLT2 and Rat2-HO6 cells (1 Â 10 4 cells) were seeded in 24-well plates and incubated for 24 h. After fixation in 4% paraformaldehyde in PBS for 20 min, the cells were washed twice with PBS and then permeabilized with 0.2% Triton X-100 for 20 min. The cells were subsequently washed again with PBS and incubated with blocking buffer (10% horse serum and 1% Bovine serum albumin in PBS) for 1 h, followed by incubation overnight at 4 1C with primary antibodies specific for BLT1 or BLT2 (Novus Biologicals Inc., Littleton, CO, USA) (1:250 dilution). The cells were washed three times with PBS and incubated with biotinylated anti-rabbit IgG, streptavidin-coupled alkaline phosphatase, and fast red violet (Alkaline phosphatase substrate system, Chemicon). Stained cells were photographed using a CKX41 microscope equipped with a DP71 digital camera (Olympus). To examine the expression of MMP-9 or BLTs in metastatic lesions of lungs and various human cancer tissue slides with formalin-fixed and paraffinembedded tissues (AccuMax array), which is purchased from Petagen Inc. (Seoul, Korea), respectively, tissue sections were deparaffinized with xylene, rehydrated with ethanol, treated with proteinase K (100 mg/ml) and incubated with blocking buffer for 30 min. Thereafter, the tissues were stained with anti-MMP-9 (1:250 dilution) or primary antibody against BLT1 or BLT2 (1:200 dilution; Novus Biologicals) for 1 h. Diaminobenzidine (Chemicon) or fast red violet solution (Chemicon) was used as the chromogen. Sections were counterstained with hematoxylin. Stained tissues were photographed using a BX51 microscope (Olympus, Tokyo, Japan) equipped with a DP71 digital camera (Olympus).
Experimental metastasis assays and morphological and histological analyses All experimental animals used in this study were treated according to the guidelines approved by the Institutional Animal Care and Use Committee of Korea University. Female nude mice (Charles River, Wilmington, MA, USA) were used in the experimental metastasis assays and were 4 weeks old at the time of injection. The details are described in the Supplementary information section. 
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